Apomorphine therapy in parkinson's disease: A review

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 16, 2007, Pages 2799-2809

  Ul Haq, Ihtsham ^a   Lewitt, Peter A ^b   Fernandez, Hubert H ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Apomorphine; Motor fluctuation; Parkinson's disease

Indexed keywords

ALOSETRON; APOMORPHINE; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; DOLASETRON MESILATE; DOMPERIDONE; DOPAMINE; GRANISETRON; LEVODOPA; ONDANSETRON; PALONOSETRON; SODIUM METABISULFITE; TEA TREE OIL; TRIMETHOBENZAMIDE; ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT;

ARTHRALGIA; AUTOIMMUNE HEMOLYTIC ANEMIA; BRADYCARDIA; CAPILLARY RESISTANCE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG OXIDATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERANCE; DYSKINESIA; ENZYME INHIBITION; FALLING; HALLUCINATION; HUMAN; INDUCED HYPOTENSION; INJECTION SITE IRRITATION; INJECTION SITE NODULE; INJECTION SITE REACTION; LACRIMATION; MAXIMUM PLASMA CONCENTRATION; MOTOR DYSFUNCTION; NAUSEA AND VOMITING; NEPHROTOXICITY; NONHUMAN; NOSE DISEASE; NOSE IRRITATION; ORTHOSTATIC HYPOTENSION; PALLOR; PARKINSON DISEASE; PRIAPISM; REVIEW; SALIVATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SWEATING; THROMBOSIS; ULTRASOUND THERAPY; UREA BLOOD LEVEL; WEAKNESS; XEROSTOMIA; YAWNING; ANIMAL;

ANIMALS; ANTIPARKINSON AGENTS; APOMORPHINE; CLINICAL TRIALS; DOPAMINE AGONISTS; HUMANS; PARKINSON DISEASE;

EID: 36049001110     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.16.2799     Document Type: Review

References (75)

1. PARKINSON STUDY GROUP: Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson study group. JAMA (2000) 284(15):1931-1938.
2. AHLSKOG JE, MUENTER MD: Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. (2001) 16(3):448-458.
3. LEWITT PA: Extending the Action of Levodopa's Effects. LeWitt PA, Oertel WH (Ed.), Martin Dunitz Publishers, London (1999):141-158.
4. MELAMED E, BITTON V, ZELIG O: Delayed onset of responses to single doses of L-dopa in parkinsonian fluctuators on long-term L-dopa therapy. Clin. Neuropharmacol. (1986) 9:182-188.
5. DEWEY RB Jr: Management of motor complications in Parkinson's disease. Neurology (2004) 62(6 Suppl. 4):S3-S7.
6. STACY M, FACTOR S: Rapid treatment of "off" episodes: will this change Parkinson's disease therapy? In: Neurology (2004):SI-S3.
7. HARDIE RJ, LEES AJ, STERN GM: On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Brain (1984) 107(Part 2):487-506.
8. FERNANDEZ HH, PAHWA R. Apomorphine as rescue therapy of off episodes in patients with advanced Parkinson's disease. Mov. Disord. (2004) 19:11-20.
9. FERNANDEZ HH, VAN LUNEN BE: Intermittent subcutaneous apomorphine: evidence for efficacy at early timepoints in Parkinsores disease. Mov. Disord. (2006) 21(Suppl. 13):110.
10. BOWRON A. Practical considerations in the use ofapomorphine injectable. Neurology (2004):S32-S36.
11. SCHWAB RS, AMADOR LV, LETTVIN JY. Apomorphine in Parkinson's disease. Trans. Am. Neurol. Assoc. (1951) 56:251-253.
12. COTZIAS GC, PAPAVASILIOU PS, TOLOSA ES, MENDEZ JS, BELL-MIDURA M: Treatment of Parkinson's disease with aporphines. Possible role of growth hormone. N. Eng. J. Med. (1976) 294(11):567-572.
13. FACTOR SA. Dopamine agonists. Med Clin. North Am. (1999) 83(2):415-443.
14. MANSON AJ, HANAGASI H, TURNER K et al.: Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations. Brain (2001) 124(Part 2):331-340.
15. ONDO W, HUNTER C, ALMAGUER M, GANCHER S, JANKOVIC J: Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease. Clin. Neurppharmacol. (1999) 22(1):1-4.
16. VAN LAART, JANSEN EN, NEEF C, DANHOF M, ROOS RA. Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. Mov. Disord. (1995) 10(4):433-439.
17. KAPOOR R, TURJANSKI N, FRANKEL J et al.: Intranasal apomorphine: a new treatment in Parkinsor's disease. J. Neurol. Neurosurg. Psychiatry (1990) 53(11):1015.
18. PRIANO L, ALBANI G, BRIOSCHI A et al.: Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease. Mov. Disord (2004) 19(8):937-942.
19. AGID Y, POLLAK P, BONNET AM, SIGNORET JL, LHERMITTE F: Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease. Lancet Neurol. (1979) 17(8116):570-572.
20. STIBE CM, LEES AJ, KEMPSTER PA, STERN GM: Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet (1988) 20(1):403-406.
21. STACY M: Apomorphine: North American clinical experience. Neurology (2004) 62(Suppl 4):S18-S21.
22. METMAN LV, LOCATELLI ER, BRAVI D, MOURADIAN MM, CHASE TN: Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology (1997) 48(2):369-372.
23. DEWEY RB Jr, HUTTON JT, LEWITT PA, FACTOR SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch. Neurol. (2001) 58(9):1385-1392.
24. SHERRY JH, GUYTON PJ, VAN LUNEN B, BOTTINI PB: Continued efficacy and safety of subcutaneous injections of apomorphine in the treatment of off episodes in patients with Parkinson's disease. Neurology (2003) 60(Suppl. 1)-A81.
25. CAMPBELL A, BALDESSARINI RJ, TEICHER MH, NEUMEYER JL: S(+)Apomorphines. Selective inhibition of excitatory effects of dopamine injected into the limbic system of the rat. Neuropharmacology (1985) 24(5):391-399.
26. HUTCHINSON WD, LEVY R, DOSTROVSKY JO, LOZANO AM, LANG AE: Effects of apomorphine on globus pallidus neurons in parkinsonian patients. Ann. Neurol. (1997) 42(5):767-775.
27. ZHANG A, ZHANG Y, BRANFMAN AR, BALDESSARINI RJ, NEUMEYER JL: Advances in development of dopaminergic aporphinoids. J. Med. Chem. (2007) 50(2):171-181.
28. KOLLS BJ, STACY M: Apomorphine: a rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease. Clin. Neuropharmacol. (2006) 29(5):292-301.
29. GANCHER S: Pharmacokinetics of apomorphine in Parkinson's disease. J. Neural Thansm. Suppl. (1995) 45:137-141.
30. LEWITT PA: Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology (2004) 62(6 Suppl. 4):S8-S11.
31. HOFSTEE DJ, NEEF C, VAN LAAR T, JANSEN EN: Pharmacokinetics of apomorphine in Parkinson's disease: plasma and cerebrospinal fluid levels in relation to motor responses. Clin. Neuropharmacol. (1994) 17(1):45-52.
32. PRZEDBORSKI S, LEVIVIER M, RAFTOPOULOS C, NAINI AB, HILDEBRAND J: Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. Mov. Disord. (1995) 10(1):28-36.
33. FACTOR SA. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease. Neurology (2004) 62(6 Suppl 4):S12-S17.
34. OSTERGAARD L, WERDELIN L, ODIN P et al.: Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study. J. Neurol. Neurosurg. Psychiatry (1995) 58:681-687.
35. KLEEDORFER B, TURJANSKI N, RYAN R et al.: Intranasal apomorphine in Parkinson's disease. Neurology (1991) 41(5):761-762.
36. DEWEY RB Jr, MARAGANORE DM, AHLSKOG JE, MATSUMOTO JY: Intranasal apomorphine rescue therapy for parkinsonian "off" periods. Clin. Neuropharmcol. (1996) 19(3):193-201.
37. MONTASTRUC JL, RASCOL O, SENARD JM et al.: Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study. Clin. Neuropharmacol. (1991) 14(5):432-437.
38. GANCHER ST, NUTT JG, WOODWARD WR: Absorption of apomorphine by various routes in parkinsonism. Mov. Disord. (1991) 6(3):212-216.
39. CAMPBELL A, KULA NS, JEPPSSON B, BALDESSARINI RJ: Oral bioavailability of apomorphine in the rat with a portacaval venous anastomosis. Eur. J. Pharmacol. (1980) 67(1):139-142.
40. PANEGYRES PY, GRAHAM SJ, WILLIAMS BK, HIGGINS BM, MORRIS JG: Sublingual apomorphine solution in Parkinson's disease. Med. J. Austr. (1991) 155(6):371-374.
41. HUGHES AJ, WEBSTER R, BOVINGDON M, LEES AJ, STERN GM: Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations. Clin. Neuropharmacol. (1991) 14(6):556-561.
42. KOLLER W, STACY M: Other formulations and future considerations for apomorphine for subcutaneous injection therapy. Neurology (2004) 62(6 Suppl. 4):S22-S26.
43. THOMAS NL, COUGHTRIE MW: Sulfation of apomorphine by human sulfotransferases: evidence of a major role for the polymorphic phenol sulfotransferase, SULTIA1. Xenobiotica (2003) 33(11):1139-1148.
44. SAM E, JEANJEAN AP, MALOTEAUX JM, VERBEKE N: Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application. Eur. J. Drug Metab. Pharmocokinet. (1995) 20(1):27-33.
45. VAN DER GEEST R, VAN LAAR T, KRUGER PP et al.: Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. Clin. Neuropharmacol, (1998) 21(3):159-168.
46. LAHTI RA, EVANS DL, STRATMAN NC, FIGUR LM: Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur. J. Pharmacol. (1993) 236(3):483-486.
47. NEWMAN-TANCREDI A, CUSSAC D, QUENTRIC Y et al.: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J. Pharmacol. Exp. Ther. (2002) 303(2):815-822.
48. PRESKORN SH, BORGES-GONZALES S, FLOCKHART D: Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: part II. J. Psychiatr. Pract. (2006) 12(5):312-316.
49. CARPENTER DO, BRIGGS DB, STROMINGER N: Responses of neurons of canine area postrema to neurotransmitters and peptides. Cell. Mol. Neurobiol. (1983) 3(2):113-126.
50. CASTRO A, MEARIN F, LARISH J, MALAGELADA JR: Gastric fundus relaxation and emetic sequences induced by apomorphine and intragastric lipid infusion in healthy humans. Am. J. Gastroenterol. (2000) 95(12):3404-3411.
51. SHERRYJH, BOTTINI PB, BURKHART GA. Electrocardiographic assessment of subcutaneous apomorphine in patients with advanced Parkinson's disease. Movement Disorder Society's. 9th International Congress of Parkinson's Disease & Movenment Disorders. New Orleans, LA (5-8 March 2005).
52. PFEIFFER RF, GUTMANN L, HULL KL JR et al.: Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease. Parkinsonism Rel. Disord. (2007) 13(2):93-100.
53. VAN LAAR T, JANSEN EN, ESSINK AW et al.: A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease. Clin. Neurol Neurosurg. (1993) 95(3):231-235.
54. KOLLER W. A double-blind placebo-controlled study of the efficacy of a single dose of subcutaneous apomorphine in advanced Parkinson's disease. 56th Annual Meeting of the American Academy of Neurology. San Francisco, CA (24 April - 01 May 2004).
55. COLZI A, TURNER K, LEES AJ: Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry (1998) 64(5):573-576.
56. KATZENSCHLAGER R, HUGHES A, EVANS A et al.: Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov. Disord. (2005) 20(2):151-157.
57. STOCCHI F, VACCA L, DE PANDIS MF et al.: Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol. Sci. (2001) 22(1):93-94.
58. HUGHES AJ, BISHOP S, LEES AJ et al.: Rectal apomorphine in Parkinso'ns disease. Lancet (1991) 337(8733):118.
59. LI GL, DE VRIES JJ, VAN STEEG TJ et al.: Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment. J. Control Rel. (2005) 101(1-3):199-208.
60. PIETZ K, HAGELL P, ODIN P: Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J. Neurol Neurosurg. Pychiatry (1998) 65(5):709-716.
61. CORSINI GL, DEL ZOMPO M, GESSA GL, MANGONI A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet (1979) 5(1):954-956.
62. MELIS MR, SUCCU S, ARGIOLAS A: Dopamine agonists increase nitric oxide production in the paraventricular nucleus of the hypothalamus: correlation with penile erection and yawning. Eur. J. Neurosci. (1996) 8(10):2056.
63. COLLINS GT, WITKIN JM, NEWMAN AH et al.: Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J. Pharmacol Exp. Ther. (2005) 314 (1):310-319.
64. PROTAIS P, DUBUC I, COSTENTIN J: Pharmacological characteristics of dopamine receptors involved in the dual effect of dopamine agonists on yawning behaviour in rats. Eur. J. Pharmacol. (1983) 94(3-4):271-280.
65. HUGHES AJ, BISHOP S, KLEEDORFER B et al.: Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov. Disord. (1993) 8(2):165-170.
66. RUGGIERI S, STOCCHI F, CARTA A, AGNOLI A: Side-effects of subcutaneous apomorphine in Parkinson's disease. Lancet (1989) 1(8646):1084-1085.
67. FRANKEL JP, LEES AJ, KEMPSTER PA, STERN GM: Subcutaneous apomorphine in the treatment of Parkinson's disease. J. Neurol Neurosurg. Psychiatry (1990) 53(2):96-101.
68. O'SULLIVAN JD, LEES AJ: Use of apomorphine in Parkinson's disease. Hosp. Med. (1999) 60(11):816-820.
69. ALBANESE A, BONUCCELLI U, BREFEL C et al.: Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. Mov. Disord. (2001) 16(2):197-201.
70. PAHWA R, FACTOR SA, LYONS KE et al.: Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurolagy (2006) 66(7):983-989.
71. PINTER MM, ALESCH F, MURG M, HELSCHER RJ, BINDER H: Apomorphine test: a predictor for motor responsiveness to deep brain stimulation of the subthalamic nucleus. J. Neurol. (1999) 246(10):907-913.
72. GALVEZ-JIMENEZ N, LANG AE: Perioperative problems in Parkinson's disease and their management. apomorphine with rectal domperidone. Can. J. Neurol. Sci. (1996) 23(3):198-203.
73. BERTEK M. Clinical Review of Apomorphine Pivotal Studies in Parkinson's Disease. In: Mylen Berrek Pharmaceuticals (2005):1-79.
74. SWINN LA, JAMES CR, QUINN NP, LEES AJ: Treatment of Parkinson's. Disease with Apomorphine (5th Edition), Queen Square, London (2005):22.
75. SWOPE DM: Rapid treatment of "wearing off" in Parkinson's disease. Neurology (204) 62(6 Suppt 4):S27-S31.